- the Food and Drug Administration approved isembyld, the company’s treatment for spinal muscular atrophy.
- Isembyld, also known as apitegromab-mstn, was approved for adults and children ages 2 and older who are already receiving a treatment targeting survival motor neuron 2, or SMN2.
- will discuss the approval and commercial rollout during an investor call Monday at 8 a.m. Eastern time.